AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS

1. (Currently amended) A method of doing business among two or more entities engaged in ~~research~~ clinical trails and development of a pharmaceutical product, wherein the ~~object of said research and development~~pharmaceutical product is the subject of a multinational patent portfolio, said method comprising:

developing the pharmaceutical product having physical characteristics and conducting clinical trials by administering said pharmaceutical product to human and animal trial subjects;

obtaining clinical trial results from said clinical trials and transforming said clinical trial results to regulatory data, wherein the clinical trial results relate to observed results of administering said pharmaceutical product to human and animal trial subjects and wherein said regulatory data may be used to obtain regulatory approval to market the pharmaceutical product in a first territory;

storing said regulatory data and information on an electronic regulatory data database residing on the memory of a computing device, wherein the information relates to the physical characteristics of the pharmaceutical product;

~~a)~~ providing a territorial distribution of at least some of the rights under said patent portfolio from a first party having rights in the multinational patent portfolio and the regulatory data and information to a second party; ~~and~~

~~b)~~ providing access to said electronic regulatory data base by the first party over a communications network to the second party, said electronic data base representing a ~~secondary~~ market for regulatory data and information, said regulatory data and information relating to the pharmaceutical product subject of the multinational patent portfolio and obtained in ~~one~~ the first party's ~~research~~ clinical trials and development whereby ~~it~~ said regulatory data and information can be ~~utilized~~ used by ~~another~~ the second party in ~~its~~ a second territory for purposes of obtaining regulatory approval to market the pharmaceutical product in the second territory.

2. (Currently amended) The method according to Claim 1,

wherein said secondary market comprises granting certain territorial rights in [[a]] the first party's regulatory data and information for an amount compensation that ~~may exceed~~ relates to [[a]]the first party's cost of development.

3. (Original) The method according to Claim 2,

wherein said compensation comprises royalty payments, the rate of which are proportional the commercial advantage conferred on the second party when the regulatory data and information is obtained.

4. (Cancelled).

5. (Currently amended) The method according to Claim [[4]]2,

wherein the territorial distribution of rights is provided by an exclusive territorial license.

6. (Currently amended) The method according to Claim [[4]]2, wherein the parties are independent entities.

7. (Currently amended) The method according to Claim [[4]]2, which involves at least three parties.

8. – 22. (Cancelled).

23. (New) The method according to Claim 1 wherein providing a territorial distribution further comprises licensing the patent rights along with the regulatory data from the first party to the second party is a licensee of the patent rights.

24. (New) The method according to Claim 1 wherein providing a territorial distribution further comprises selling the patent rights along with the regulatory data from the first party to the second party.

25. (New) The method according to Claim 1 further comprising transforming the regulatory data to regulatory data that complies with the regulatory requirements of the second territory.